Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus

  title={Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus},
  author={Tomoko Syuto and Akira Shimizu and Yuko Takeuchi and Setsuko Tanaka and Michiko Hasegawa and Yayoi Nagai and Atsushi Tamura and Osamu Ishikawa},
  journal={Clinical Rheumatology},
Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE) are well-recognized symptoms although the pathophysiology of neuropsychiatric SLE (NPSLE) is unclear. Since an association with antiphospholipid antibodies has been reported, we examined the prevalence of antiphosphatidylserine–prothrombin antibodies (anti-PS/PT Abs), lupus anticoagulant (LA), anticardiolipin/β2-glycoprotein I antibodies (anti-β2-GPI Abs), and antiribosomal P protein antibodies (antiribosomal P… 

Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus

APS/PT antibodies provide non-redundant information that could contribute to risk assessment and stratification of patients with SLE, but had limited predictive values for damage progression in the short term.

Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome

Anti-PS/PT antibody assays demonstrated high diagnostic performance for Chinese patients with APS, detected some APS patients negative for criteria markers and may serve as potential risk predictors for venous thrombosis and obstetric complications.

Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE

In this cross-sectional study, non-criteria APL were not associated with CI, and using multiple linear regression and adjusting for relevant covariates including age, ethnicity, and family income, neither the presence nor the titer of any non-critical APL significantly influenced TTS.

The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation

The introduction of aPS/PT antibodies in the diagnostic process of APS is highly recommended, since they disclose a notable diagnostic performance and a high correlation with LA activity, such that they can be a viable alternative.

Impact Analysis of Autoantibody Level and NR2 Antibody Level in Neuropsychiatric SLE Treated by Methylprednisolone Combined with MTX and DXM Intrathecal Injection

Anti-NR2 antibody can be a screening index of NPSLE, and methylprednisolone combined with MTX and DXM intrathecal injection has significant curative effects and can effectively decrease autoantibody level and anti- NR2 antibody level.

Subclinical neuropsychiatric dysfunctions in female patients with systemic lupus erythematosus

A significant number of patients with SLE without overt NP manifestations had subclinical cerebrovascular and cognitive dysfunctions, depression, and anxiety by simple bedside questionnaires, and SLE disease activity positively correlates with NP manifestations.


The steps of this research will be including the sequence analysis followed by Phylogenetic analysis on the protein sequence, structural analysis and drug molecule selection, and sterol proves to be the best compound.



A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus.

The data suggest an association between LAC and cerebrovascular disease at the time of SLE diagnosis and chorea over the disease course, but not between aPL and other neuropsychiatric manifestations.

Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis

Examining the frequency and clinical association of antiphosphatidylserine-prothrombin complex (PS/PT) antibody (Ab) in systemic sclerosis (SSc) found it to be associated with thromboembolism, peripheral ischaemia, and lung involvement in some patients with SSc.

The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus.

It was showed that positive results of anti-beta2-GPI-ELISA and anti-PS/PT- ELISA could serve as markers of thrombotic complications in patients with SLE, whereas aCL andAnti-PT are less reliable as marker of these complications.

Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies.

The new ACR criteria for NPSLE are useful to define NP manifestations in SLE with accuracy and are significantly associated with antiphospholipid antibodies, which are independently associated with CVD, headache, and seizures.

Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus.

The presence of aCL/beta2-GPI contributes to the risk of development of ASO, which may represent an important mechanism for the pathogenesis of IHD in patients with SLE.

Hemichorea with antiphospholipid antibodies in a patient with lupus nephritis

A 7-year-old boy suffered from lupus nephritis and a left middle cerebral artery infarction and subsequently experienced two episodes of right hemichorea associated with increased aPLs levels without any evidence of further neurological lesions by brain computed tomography or magnetic resonance imaging.

Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis.

Anti-P antibody testing has limited diagnostic value for NPSLE, and it is not helpful in differentiating among various disease phenotypes.

Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro.

Results indicate that anti-CL/beta2-GPI and anti-PS/PT may cooperate to promote platelet activation, which may contribute to the risk of cerebral infarction in patients with SLE.

Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.

In patients with SLE, NP disease has diverse manifestations and can be attributed to lupus in roughly half of the cases, and the occurrence of NP disease is associated with a significant reduction in quality of life.